Navigation Links
NeoStem to Present at LifeTech Capital Miami Medical Investors Conference
Date:11/10/2010

NEW YORK, Nov. 10, 2010 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Chief Executive Officer Robin Smith, M.D., MBA, will present on some of the latest developments at the Company at the LifeTech Capital Miami Medical Investors Conference to be held at the JW Marriott Marquis Miami on November 12, 2010. In addition, Dr. Smith has been selected to appear on a science and industry panel with the leading medical researchers from the University of Miami Miller School of Medicine.

Dr. Smith will participate in the Innovations in Science & Industry Panel #1 from 8:30 am to 9:00 am in the Main Ballroom and then will present from 9:30 am to 9:50 am in Presentation Room #1.

The LifeTech Capital Miami Medical Investors Conference brings together promising biotechnology companies and medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at http://www.LifeTechCapital.com/conference.

"I am excited to present on NeoStem's latest developments at the first annual LifeTech Capital Miami Medical Investors Conference. I look forward to providing details on our recent research and development efforts and partnerships, especially those looking at potential applications of our VSEL™ Technology," said Dr. Robin Smith.

About NeoStem, Inc.NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contactRobin Smith

NeoStem, Inc.Phone: +1 (212) 584-4174E-mail: rsmith@neostem.comhttp://www.neostem.com
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStems Licensed Adult Stem Cell Treatments for Orthopedic Applications in China
2. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
3. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
4. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
5. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
6. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
7. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
8. NeoStem Announces Warrant Exercise by Principal Shareholder
9. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
10. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
11. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
Breaking Medicine News(10 mins):